JAGX News & Events

Jaguar Health provided a recap of presentations of the oral liquid crofelemer as adjunctive therapy in pediatric intestinal failure, IF, patients at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition, ESPGHAN, Meeting in Lille, France. Napo provided additional data from ongoing investigational studies with oral liquid crofelemer in pediatric patients with IF due to microvillus inclusion disease, MVID, and short bowel syndrome, SBS. Since IF patients cannot orally absorb adequate nutrients, electrolytes and fluids, they require lifelong total parenteral nutrition, TPN, with or without supplemental intravenous fluids, which together comprise parenteral support, PS, for up to seven days per week and up to 20+ hours per day. As presented at ESPGHAN 2026, the results of ongoing investigations of liquid oral crofelemer demonstrate substantial reductions of PS and PS normalized to body weight in pediatric IF patients dosed orally for more than one year, with no significant clinical or laboratory abnormalities. In one MVID patient, the weekly PS requirements normalized to body weight have been reduced by up to 48% following greater than 12 months of liquid oral high-dose crofelemer therapy. In two pediatric SBS-IF patients, weekly PS requirements normalized to body weight were reduced up to 40% following greater than12 months of liquid oral high dose crofelemer therapy.

Jaguar Health hereby notifies holders of its Series O Convertible Preferred Stock, par value $0.0001 per share, that the Company has exercised its right to cause the optional conversion of the Preferred Stock pursuant to Section 6(a) of the Certificate of Designation of Preferences, Rights and Limitations of Series O Convertible Preferred Stock. Each share of Preferred Stock will automatically be converted into 3.209 shares of voting common stock, par value $0.0001 per share, of the Company at 12:00 pm Eastern Time on June 25, 2026. Fractional shares of Common Stock will not be issued as a result of the conversion of the Preferred Stock. Instead, holders of shares of Common Stock who otherwise would have been entitled to receive a fractional share as a result of the conversion will receive an amount in cash equal to the fair value of such fractional interest, based on a price per share of $2.68, the closing price per share of Common Stock on June 24, as reported on the Nasdaq Stock Market. No action by holders of the Preferred Stock is required. As announced February 18, Jaguar's Board of Directors declared a one-time special stock dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on March 2. The Special Stock Dividend consisted of the Preferred Stock. Only persons who owned shares of the Company's Common Stock, or certain warrants to purchase Common Stock with dividend rights, at the close of business on the March 2 record date were entitled to receive shares of the Preferred Stock.

Jaguar Health announced that the company has completed submission of its New Animal Drug Application, NADA, to the U.S. Food and Drug Administration's Center for Veterinary Medicine for full approval of crofelemer for the treatment of chemotherapy-induced diarrhea, CID, in dogs. "We're very happy to have completed submission of this NADA," said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar's Vice President of Preclinical and Nonclinical Studies. "As announced, the statistically significant results of our recently completed pivotal effectiveness study of Canalevia-CA1 for the treatment of CID in dogs demonstrated that dogs suffering from CID who were treated with Canalevia-CA1 twice daily at the onset of diarrhea had, at the end of 3 days of treatment, an average daily stool that was regarded as normal. Moreover, in a survey at the end of the study, 77% of the owners of dogs participating in the study reported that they believed Canalevia-CA1 was an effective treatment for their dog's CID. Additionally, around 40% of dog owners reported that Canalevia-CA1 completely resolved their dog's CID. In comparison, only 10.5% of owners reported complete resolution in their dog's CID without the use of any CID treatments."

Jaguar Health announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and aligned with our anticipated completion of the clinical work supporting our filing of a New Drug Application, NDA, by the Company for our crofelemer-based prescription drug candidate for rare intestinal failure diseases. Strategic alternatives under consideration may include, but are not limited to mergers, reverse mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, and may involve biotech or non-biotech companies.